Table 1.
Demographic and clinical characteristics of subjects.
| AS (n = 50) | HC (n = 50) | Z/χ2 | P value | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age (year) | 34.00 (26.00-46.25) | 34.00 (26.00-47.00) | -0.069 | 0.945 |
| Gender (male, %) | 37 (74.0%) | 37 (74.0%) | <0.001 | 1.000 |
| Clinical characteristics | ||||
| WBC (×109/L) | 6.42 (5.50-7.68) | – | ||
| NEU (×109/L) | 3.90 (2.92-4.58) | – | ||
| MON (×109/L) | 0.45 (0.35-0.61) | – | ||
| PLT (×109/L) | 225.50 (207.75-267.75) | – | ||
| LYM (×109/L) | 1.86 (1.61-2.27) | – | ||
| RDW (fL) | 42.05 (39.98-45.45) | – | ||
| PCT (%) | 6.42 (5.50-7.68) | – | ||
| HLA-B27 (+, %) | 49 (98.0%) | – | ||
| ESR (mm/h) | 12.00 (5.00-24.25) | – | ||
| CRP (mg/L) | 5.45 (2.33-14.25) | – | ||
| BASDAI (cm) | 1.60 (0.37-3.00) | – | ||
| BASFI (cm) | 0.30 (0.00-2.35) | – | ||
| ASDAS (cm) | 2.06 (1.73-2.62) | – | ||
| Disease duration (month)‡ | 12.00 (6.00-51.00) | – | ||
| Global pain (cm) | 2.00 (0.00-5.00) | |||
| Night pain (cm) | 2.50 (0.00-5.00) | |||
| FFD (cm) | 8.00 (0.75-21.75) | |||
| Chest expansion (cm) | 3.00 (3.00-4.25) | |||
| Schober test (cm) | 7.50 (5.00-10.25) | |||
| PWD (cm) | 1.00 (0.00-2.00) | |||
| Treatment (n, %) | ||||
| DMARDs | 23 (46.0%) | |||
| NSAIDs | 27 (54.0%) | |||
| Biologic agents | 22 (44.0%) |
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; FFD, Finger-floor distance; HC, healthy control; LYM, lymphocyte; MON, monocyte; NEU, neutrophil; NSAIDs, nonsteroidal anti-inflammatory drugs; PCT, plateletcrit; PLT, platelet; PWD, pillow wall distance; RDW, red cell distribution width; WBC, white blood cell; -, not available.
Statistical methods: Mann-Whitney U test and Chi-square test.
All data were expressed as median (inter-quartile range).